LTRN
Lantern Pharma Inc. Common Stock
Reaalajas hind
Hinnagraafik
Põhinäitajad
Turunäitajad
Avatud
$3.230
Kõrge
$3.230
Madal
$3.230
Maht
0.11M
Ettevõtte fundamentaalnäitajad
Kauplemisstatistika
Seotud uudised
Lantern Pharma Reports First Quarter 2025 Financial Results and Business Updates
Completion of LP-184 Phase 1a clinical trial enrollment with 62-65 patients across a range of solid tumors expected by end of June 2025. Additional patient data readout from the HARMONIC™ Trial evaluating
Lantern Advances Drug Candidate LP-184 with IND Clearance for Phase 1b/2 Clinical Trial in Triple Negative Breast Cancer (TNBC)
The FDA has cleared the investigational new drug (IND) application of LP-184 in triple negative breast cancer (TNBC) treatment – a novel small molecule advanced and developed with Lantern's AI platform,
Seotud aktsiad
RGS
Regis Corporation
CRD/A
Crawford & Company
PNFPP
Pinnacle Financial Partners Inc. Depositary shares of Pinnacle Financial Partners Inc. each representing a 1/40th Interest in a share of its 6.75% Fixed-Rate Non-Cumulative Perpetual Preferred Stock Series B
CCIXU
Churchill Capital Corp IX Unit
CUBI
Customers Bancorp Inc
Püsi kursis
Määrake hinnateavitused, hankige tehisintellekti analüüsi uuendusi ja reaalajas turuuudiseid.